FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2618360530> ?p ?o ?g. }

• W2618360530 endingPage "438" @default.
• W2618360530 startingPage "433" @default.
• W2618360530 abstract "Objective: This study was designed to compare the clinical efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma (HCC). Methods: From March 2015 to August 2015, a total of 44 patients with moderate and advanced HCC, who were admitted in the Navy General Hospital of China, were included into this study. These patients were randomly divided into 2 groups: group A and group B. Patients in group A underwent TACE alone, while patients in group B underwent the combined treatment of TACE with apatinib. Differences in preoperative general data between these 2 groups were not statistically significant (P > 0.05). All patients were followed up for 12–18 months. Changes in α-fetal protein (AFP) at 3 months after treatment and the objective response rate (ORR) at 3, 6, 9 and 12 months after treatment were compared between these 2 groups. Furthermore, progression-free survival (PFS) and the incidence of adverse reactions were also compared between these 2 groups. Results: AFP levels in groups A and B significantly decreased after 3 months of treatment, compared with the levels before treatment, and the differences were statistically significant (P < 0.05). However, at 3 months after treatment, the difference between these 2 groups was not statistically significant (P > 0.05). ORR at 3, 6, 9 and 12 months after treatment was 36.36%, 27.27%, 13.64% and 9.09%, respectively, in group A; and 60%, 50%, 45% and 35%, respectively, in group B. At 3 and 6 months after treatment, the differences between these 2 groups were not statistically significant (P > 0.05); while at 9 and 12 months after treatment, the differences between these 2 groups were statistically significant (P < 0.05). The median PFS was 6.0 months in group A and 12.5 months in group B, and the difference was statistically significant (P < 0.05). The incidences of complications were related to oral apatinib, such as hypertension, hand-foot syndrome and proteinuria, were higher in group B than in group A, and the differences were statistically significant (P < 0.05). These symptoms all alleviated after symptomatic treatments. Conclusions: For intermediate and advanced HCC, the long-term curative effect of TACE combined with apatinib is better than that of TACE alone. The former can obviously prolong the PFS of patients and has a confirmed safety." @default.
• W2618360530 created "2017-06-05" @default.
• W2618360530 creator A5000767036 @default.
• W2618360530 creator A5018752530 @default.
• W2618360530 creator A5029282098 @default.
• W2618360530 creator A5032721803 @default.
• W2618360530 creator A5036142692 @default.
• W2618360530 creator A5050475802 @default.
• W2618360530 creator A5072749419 @default.
• W2618360530 creator A5075980805 @default.
• W2618360530 creator A5084821441 @default.
• W2618360530 date "2017-05-26" @default.
• W2618360530 modified "2023-10-18" @default.
• W2618360530 title "Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial" @default.
• W2618360530 cites W1969947714 @default.
• W2618360530 cites W1971837077 @default.
• W2618360530 cites W1975154077 @default.
• W2618360530 cites W1996229105 @default.
• W2618360530 cites W2012834220 @default.
• W2618360530 cites W2026799786 @default.
• W2618360530 cites W2056163905 @default.
• W2618360530 cites W2063488708 @default.
• W2618360530 cites W2079586464 @default.
• W2618360530 cites W2085106601 @default.
• W2618360530 cites W2093677498 @default.
• W2618360530 cites W2105968397 @default.
• W2618360530 cites W2140765540 @default.
• W2618360530 cites W2213448039 @default.
• W2618360530 cites W2293170306 @default.
• W2618360530 doi "https://doi.org/10.1080/15384047.2017.1323589" @default.
• W2618360530 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5536939" @default.
• W2618360530 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28548587" @default.
• W2618360530 hasPublicationYear "2017" @default.
• W2618360530 type Work @default.
• W2618360530 sameAs 2618360530 @default.
• W2618360530 citedByCount "88" @default.
• W2618360530 countsByYear W26183605302017 @default.
• W2618360530 countsByYear W26183605302018 @default.
• W2618360530 countsByYear W26183605302019 @default.
• W2618360530 countsByYear W26183605302020 @default.
• W2618360530 countsByYear W26183605302021 @default.
• W2618360530 countsByYear W26183605302022 @default.
• W2618360530 countsByYear W26183605302023 @default.
• W2618360530 crossrefType "journal-article" @default.
• W2618360530 hasAuthorship W2618360530A5000767036 @default.
• W2618360530 hasAuthorship W2618360530A5018752530 @default.
• W2618360530 hasAuthorship W2618360530A5029282098 @default.
• W2618360530 hasAuthorship W2618360530A5032721803 @default.
• W2618360530 hasAuthorship W2618360530A5036142692 @default.
• W2618360530 hasAuthorship W2618360530A5050475802 @default.
• W2618360530 hasAuthorship W2618360530A5072749419 @default.
• W2618360530 hasAuthorship W2618360530A5075980805 @default.
• W2618360530 hasAuthorship W2618360530A5084821441 @default.
• W2618360530 hasBestOaLocation W26183605301 @default.
• W2618360530 hasConcept C120665830 @default.
• W2618360530 hasConcept C121332964 @default.
• W2618360530 hasConcept C126322002 @default.
• W2618360530 hasConcept C141071460 @default.
• W2618360530 hasConcept C168563851 @default.
• W2618360530 hasConcept C197934379 @default.
• W2618360530 hasConcept C2777546739 @default.
• W2618360530 hasConcept C2777785397 @default.
• W2618360530 hasConcept C2778019345 @default.
• W2618360530 hasConcept C2778455285 @default.
• W2618360530 hasConcept C2780073493 @default.
• W2618360530 hasConcept C2780668389 @default.
• W2618360530 hasConcept C2780678043 @default.
• W2618360530 hasConcept C3019894029 @default.
• W2618360530 hasConcept C535046627 @default.
• W2618360530 hasConcept C61511704 @default.
• W2618360530 hasConcept C71924100 @default.
• W2618360530 hasConcept C90924648 @default.
• W2618360530 hasConceptScore W2618360530C120665830 @default.
• W2618360530 hasConceptScore W2618360530C121332964 @default.
• W2618360530 hasConceptScore W2618360530C126322002 @default.
• W2618360530 hasConceptScore W2618360530C141071460 @default.
• W2618360530 hasConceptScore W2618360530C168563851 @default.
• W2618360530 hasConceptScore W2618360530C197934379 @default.
• W2618360530 hasConceptScore W2618360530C2777546739 @default.
• W2618360530 hasConceptScore W2618360530C2777785397 @default.
• W2618360530 hasConceptScore W2618360530C2778019345 @default.
• W2618360530 hasConceptScore W2618360530C2778455285 @default.
• W2618360530 hasConceptScore W2618360530C2780073493 @default.
• W2618360530 hasConceptScore W2618360530C2780668389 @default.
• W2618360530 hasConceptScore W2618360530C2780678043 @default.
• W2618360530 hasConceptScore W2618360530C3019894029 @default.
• W2618360530 hasConceptScore W2618360530C535046627 @default.
• W2618360530 hasConceptScore W2618360530C61511704 @default.
• W2618360530 hasConceptScore W2618360530C71924100 @default.
• W2618360530 hasConceptScore W2618360530C90924648 @default.
• W2618360530 hasIssue "6" @default.
• W2618360530 hasLocation W26183605301 @default.
• W2618360530 hasLocation W26183605302 @default.
• W2618360530 hasLocation W26183605303 @default.
• W2618360530 hasLocation W26183605304 @default.
• W2618360530 hasOpenAccess W2618360530 @default.
• W2618360530 hasPrimaryLocation W26183605301 @default.
• W2618360530 hasRelatedWork W2141896878 @default.

• next